


PHARMACEUTICAL 2022



Turning Point Therapeutics Inc. Rank 49 of 466





PHARMACEUTICAL 2022





Turning Point Therapeutics Inc. Rank 49 of 466

The relative strengths and weaknesses of Turning Point Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Turning Point Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Turning Point Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 9.8% points.

The company's Economic Capital Ratio, given in the ranking table, is 268%, being 190% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	992,462
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	47,089
Liabilities, Non-Current	0
Other Assets	7,179
Other Compr. Net Income	-1,483
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	32,278
Property and Equipment	3,822
Research and Development	192,979
Selling, General and Administrative Expense	75,850

Output Variable	Value in 1000 USD
Assets	1,003,463
Liabilities	47,089
Expenses	268,829
Revenues	32,278
Stockholders Equity	956,374
Net Income	-236,551
Comprehensive Net Income	-237,292
Economic Capital Ratio	268%

